Abstract:Glycogen synthase kinase‐3β (GSK‐3β) is a crucial regulator of various cellular functions and is implicated in numerous diseases including neurological disorders. 3D QSAR model was developed with 157 pyrimidinone derivatives using Schrödinger. Structure‐based virtual screening, molecular dynamics simulations, ADME, MM/PBSA, and DFT studies were also performed for the identification of potential hits. Glycogen synthase kinase‐3β (GSK‐3β) plays pivotal role in regulating diverse range of cellular functions. It plays negative role in cellular signaling pathways and believed to involved in the pathologies of various diseases like neurological disorders, type II diabetes, inflammation, cardiac hypertrophy, cancer and bipolar disorders. GSK‐3β is proposed as a promising target for drug discovery in treating these disease conditions. A number of structurally different chemical scaffolds including pyrimidinone derivatives have been identified as potential GSK‐3β inhibitors. In the current study, PHASE module of Schrödinger 3D QSAR was used on about 157 pyrimidinone derivatives for the development of statistically significant PLS model. Consecutively, the best pharmacophore hypothesis with features like three hydrogen bond acceptors (A1‐3), two hydrophobic regions (H1 and H2), and one aromatic ring (R1), was selected to screen ZINC and PUBCHEM databases. Molecules with matching pharmacophoric features and ROF were subjected to structure‐based virtual screening (HTVS→SP→XP) and MMGBSA. Two hits from each library were selected for MD simulation studies that showed good pharmacokinetic properties, binding score (−6.8–−8.8 kcal/mol) and ▵GMMGBSA (−55.80–−58.1 kcal/mol) as compared to the reference molecule, NP‐12. Similarly, MD simulation, and MMPBSA identified three compounds i. e. ZINC67743231, ZINC01582756, and PUBCHEM11553018 displaying stability in the binding pocket and demonstrated better binding affinity of −22.07, −27.33, and −30.61 kcal/mol, respectively, within the active site of GSK‐3β. DFT studies also demonstrated the stability of these three lead compounds with a high energy gap between HOMO and LUMO ranging between 0.14546 and 0.1718 eV.

Role of GSK-3β Inhibitors: New Promises and Opportunities for Alzheimer's Disease

Roles of Glycogen Synthase Kinase 3 in Alzheimer’s Disease

Targeting glycogen synthase kinase-3 β for Alzheimer's disease: Recent advances and future Prospects

GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease

Targeting Glycogen Synthase Kinase-3Β for Alzheimer's Disease: Recent Advances and Future Prospects

GSK3: A potential target and pending issues for treatment of Alzheimer's disease

Glycogen Synthase Kinase 3 Inhibitors in the Next Horizon for Alzheimer's Disease Treatment

GSK-3 in Neurodegenerative Diseases

Unlocking hope: GSK-3 inhibitors and Wnt pathway activation in Alzheimer's therapy

Discovery of 2-(Anilino)pyrimidine-4-carboxamides as Highly Potent, Selective, and Orally Active Glycogen Synthase Kinase-3 (GSK-3) Inhibitors

Identification of novel brain penetrant GSK-3β inhibitors toward Alzheimer's disease therapy by virtual screening, molecular docking, dynamic simulation, and MMPBSA analysis

Discovery of Small‐Molecules as Potential GSK‐3β Inhibitors for the Treatment of Alzheimer's Disease Using Pharmacophore‐Based Virtual Screening

Design, synthesis, and biological evaluation of tetrahydropyrimidine analogue as GSK-3β/Aβ aggregation inhibitor and anti-Alzheimer's agent

Studies of glycogen synthase kinase-3 inhibitors

Discovery of new acylaminopyridines as GSK-3 inhibitors by a structure guided in-depth exploration of chemical space around a pyrrolopyridinone core.

GSK3 in Alzheimer's Disease: Mind the Isoforms

Design, Bio‐evaluation and Molecular Dynamics Simulation of Novel GSK‐3β Inhibitors

Therapeutic Potential Effect of Glycogen Synthase Kinase 3 Beta (GSK-3β) Inhibitors in Parkinson Disease: Exploring an Overlooked Avenue

Development of Inhibitors Targeting Glycogen Synthase Kinase-3Β for Human Diseases: Strategies to Improve Selectivity.

The Role of Glycogen Synthase Kinase 3 Beta in Neurodegenerative Diseases

Biological Evaluation and Energetic Analyses of Novel GSK‐3β Inhibitors